Date :
Place : United States of America, Boston
Website :http://go.evvnt.com/2732400-0?pid=80
Contact Person:Erin Thomas
Description:
Uniting Brand-New Faces Across Biotech and Pharma to Capitalize on Ground-Breaking Progress and Accelerate a New Era of Neurodegenerative Therapeutics. Time: 8:30 AM - 5:00 PM. Prices: USD 2999.00 - USD 5563.00.Deadline for abstracts/proposals : 18th March 2025
Organized By :
Keynote Speakers :
Conference Highlights :Home | 13th Alzheimer’s & Parkinson’s Drug Development Summit
Uniting Biotech & Pharma to Fuel the Next Wave of Neurodegenerative Drug Discovery, Translation & Clinical Progress
Uniting Brand-New Faces Across Biotech & Pharma to Capitalize on Ground-Breaking Progress & Accelerate a New Era of Neurodegenerative Therapeutics
In 2025, the spotlight is on neurodegenerative drug development, driven by the triumph ofLecanemabandDonanemab, coupled with rapid advancements to enablepresymptomatic diagnosis,reinvigorating the space with new targets, modalities, and technologies. Meanwhile significant advancements to target the likes ofα-synuclein,NLRP3andGBAsuggest only amatter of timeuntil a disease-modifying therapy emerges on the scene for Parkinson’s too.
Capitalizing on a new era of revitalized hope and momentum, the13thAlzheimer’s & Parkinson’s Drug Development Summitreturns as the onlyindustry-focusedandend-to-endmeeting, with comprehensive coverage spanning early discovery through to late clinical, regulatory, and commercial development.
Joinindustry’s premier gatheringof150+Alzheimer’s and Parkinson’s experts, with pioneering insights from the likes ofEisai,Eli Lilly,Biogen, andRoche, as they address their most pressing challenges in a collaborative atmosphere to spearhead the next wave of more truly transformative neurodegenerative therapeutics.
Associate Vice President
Check the event website for more details.